Arena Pharma: FDA Approval of First Weight-Loss Drug in 13 Years $ARNA

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) engages in the clinical development of biotechnology products, primarily focused on the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.  Arena has generated massive buzz as of late with the much-publicized FDA approval of obesity drug lorcaserin (Belviq).  While the results of clinical trials have demonstrated a modest 5% reduction in weight compared to placebo controls, the continued obesity epidemic in the United States has created a massive consumer base that is actively looking for an answer.  While this answer may be Belviq, it will need stronger data before the drug receives backing from insurers. With an estimated 42 percent of the U.S. population facing obesity by 2030, the announcement of Belviq’s FDA approval helped catalyze an intraday appreciation of as much as 53 percent during Wednesday last week, only to be followed by a 10% cool down the following day.  Nevertheless, Arena’s move to commercialize this potentially lucrative product has undoubtedly gained the attention of competitors Vivus (VVUS) and Orexigen Therapeutics (OREX).

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

At the end of the 1st quarter of this financial year, there were a total of 9 hedge funds invested in Arena Pharmaceutials, with a modest net investment of $13.8 million of its $1.87 billion total market capitalization.  This compares to $597.8 million of hedge fund activity within Vivus ($2.84 billion market cap) and $38.2 million of capital invested in Orexigen ($399.88 million market cap).  The holders of Arena’s stock includes Daniel GoldDE ShawIsrael Englander, Glenn Russell Dubin and quant guru Jim Simons, among others.  While the FDA’s approval is a positive sign for ARNA’s strategy going forward, this endorsement may have already been priced into the market, as the stock has risen over 450% in the last three months.  How the company translates the government’s authorization into a commercial success is yet to be seen.  In 2010, Arena made a deal with Japan’s Eisai company for Belviq. Arena will receive an upfront payment of $50 million from Japan’s Eisai company and up to another $90 million in milestone payments for U.S. approval and delivery of the product for sale. Also under agreement, Arena will receive 31.5% on the net sale from Eisai and 36.5% on the portion that exceeds $ 750 million.  As Arena reported a first quarter loss of $ 29.4 million and has 4 drugs in the first stage of development, the regulatory success of Belviq was of critical importance to the future of Arena Pharmaceuticals.

Last week witnessed another regulatory development with regard to the passage of President Obama’s Affordable Care Act.  The Supreme Court’s decision to uphold the highly controversial individual mandate and the legislation’s collective components are expected to have a negligible impact on the pharmaceutical industry.  S&P Equity Research has projected a 2%-3% increase in revenues stemming from extending health insurance coverage to 32 million presently uninsured Americans, which would roughly offset the already-agreed-to Medicare Part D price discounts, higher Medicaid rebates, and new fees.

Belviq’s FDA approval has also led to positive sentiment surrounding VVUS and OREX shares, as the likelihood that their weight loss drugs Qnexa and Contrave, respectively, will be approved has increased as well.  OREX has seen an appreciation of over 70% in the last 30 days, and VVUS stock has appreciated nearly 10% in the last 5 days.  The negative earnings of these three companies are reflected in their negative PEG ratios; ARNA at -1.14, VVUS at -1.63, and OREX at -0.34 over a 5 year projected horizon.  ARNA has a gross margin of 0.41 compared to -2.80 for OREX, which reflects that ARNA is retaining more on each dollar of sales relative to servicing its other costs and obligations.  Free cash flow yields for ARNA, OREX, and VVUS are -4.30%, -6.26% and -1.57% respectively.  Five-year growth projections for ARNA are at 25%, and should be looked at cautiously given the anticipated passage of weight loss drugs from its competitors.  In addition, ARNA has displayed a strong degree of positive correlation with the ‘VIX’ index over the last 60 days, indicating that the stock has generally outperformed the market when uncertainty has spiked.  The potential market size of obesity drugs is extraordinary, with only a 1.2% penetration of the market producing a possible $1.8 billion dollars in US sales by 2018.  Nonetheless, the sheer dependency that large pharmaceutical companies have on a core portfolio of drugs, and in this case, a single drug, makes us hesitant to commit fully to Arena Pharmaceuticals.  Assuming an earnings per share of $0.79 in 2017, and discounted at a 20% growth rate with a Price-to Earnings multiple of 25, the intrinsic value of ARNA is approximately $10/share. Given the recent rally among ARNA and its competitors, one would be wise to wait until further clinical trials have reinforced the efficacy of this potentially blockbuster drug. Until then, the landscape of this industry makes Arena’s Belviq product highly vulnerable to competition.

Note: This article is written by Mohsen Ghazi.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!